Navigation Links
Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
Date:12/10/2012

nificant proportion of patients don't respond to current therapy and these treatments have dose-limiting side effects. As a result, EMA401 is being developed as a potential first-in-class oral treatment for chronic pain, including neuropathic pain, without central nervous system side effects.

Spinifex Pharmaceuticals CEO Tom McCarthy said: "Today's announcement marks another significant step in the development of EMA401 and for Spinifex. Our recent results for EMA401 in PHN served to highlight its potential as an entirely novel approach for the treatment of neuropathic pain. We look forward to completing this study in a second key indication and to moving EMA401 further towards being an important treatment for broader chronic and neuropathic pain indications."

Lead Investigator, Professor Praveen Anand, said: "The pain associated with CIPN can be extremely debilitating and may affect the quality of life of patients for years, even when the cancer is in remission. Further, CIPN symptoms are a major reason for cancer treatments to be reduced or stopped early. The use of an AT2 receptor antagonist as a treatment for neuropathic pain is a highly innovative approach and, in addition to the strong Phase 2 results already seen by the company, my own group has undertaken non-clinical work which is highly compelling. EMA401 could represent a valuable new option for patients in an area where there is a clear need for new medicines."

As described above EMA401 is an AT2 receptor antagonist. The discovery that AT2 receptor antagonists offer an innovative approach to the treatment of neuropathic and inflammatory pain was originally made by Professor Maree Smith at The University of Queensland. Having acquired the technology, Spinifex has conducted a comprehensive pre-clinical and early clinical development program on EMA401. Spinifex continues to conduct research into the role of the AT2 receptor in nociceptive, inf
'/>"/>

SOURCE Spinifex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
2. Blue Belt Technologies Announces Golden Jubilee National Hospital Completes Initial NavioPFS Unicondylar Knee Replacement Surgery
3. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
4. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
6. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
7. OrthoAccel Technologies, Inc. Announces Appointment of New Chief Financial Officer
8. Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
9. Savient Announces the Election of Robert G. Savage to its Board of Directors
10. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
11. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 A new report ... (Product type, Form, End user, Application and Geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... Based on key trends tracked, it is anticipated that ... billion by 2020, registering a CAGR of 6.2% from ...
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Second quarter overview: , Revenues of $53.9 million, ... Diluted EPS of $0.24, up 33% over last year,s ... revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... Internal Pipeline as DARA Program Enters ... SARM Program is Added, PRINCETON, N.J., Nov. 1 ... and nine months ended,September 30, 2007, and highlighted several ... since the beginning,of the quarter. During the third ...
... Calif., Nov. 1 IDM Pharma, Inc.,(Nasdaq: IDMI ... the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The,trial ... cooperative,group study conducted by the Children,s Oncology Group (COG) ... patients originally treated in the Phase,3 trial. The results ...
Cached Medicine Technology:Pharmacopeia Announces Third Quarter 2007 Financial Results 2Pharmacopeia Announces Third Quarter 2007 Financial Results 3Pharmacopeia Announces Third Quarter 2007 Financial Results 4Pharmacopeia Announces Third Quarter 2007 Financial Results 5Pharmacopeia Announces Third Quarter 2007 Financial Results 6Pharmacopeia Announces Third Quarter 2007 Financial Results 7Pharmacopeia Announces Third Quarter 2007 Financial Results 8Pharmacopeia Announces Third Quarter 2007 Financial Results 9Pharmacopeia Announces Third Quarter 2007 Financial Results 10Pharmacopeia Announces Third Quarter 2007 Financial Results 11IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 2IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 3IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 5IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 6
(Date:10/22/2014)... 22, 2014 On Saturday, October 25, 2014, ... annual family health and fitness fair ¡Vive tu vida! Get ... and good nutrition for better health and wellness for people ... free and open to the public, will be held at ... 9:00 am to 1:00 pm. , “¡Vive tu Vida! ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... Mission Viejo, CA (PRWEB) October 22, 2014 ... that Jay Cormier, Sr. Vice President of Sales, will ... at the upcoming Meetings Technology Expo on October 28, ... will also be hosting a booth as well as ... on how Lintelus Meeting can create a more engaging ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... the sexes, findings show, , TUESDAY, Feb. 2 (HealthDay News) ... research indicates. , ""Our study shows that the relationship between ... in boys as it is in girls," study author Dr. ... Michigan, said in a university news release. "We found that ...
... ... Applicant Tracking System and Screening services. , ... Citrus Heights, CA (PRWEB) February 2, 2010 -- HR Allen ... efficient HRIS system, a web-based paperless Applicant Tracking System and an accurate, timely and ...
... , , FOUNTAIN HILLS, Ariz. , ... SNDZ), an innovative developer of safe and noninvasive therapies for ... and Scientific Social Solutions Charitable Foundation (S3) to provide medical ... former starting pitcher for the Boston Red Sox and New ...
... , , , LOS ANGELES , ... local, lost 143 lbs while eating fast food! He did this without ... to lose weight and have a career as a model/actor/comedian, LaVelle LaRue ... day. Like many of today,s busy Americans, he did not have the time ...
... it,s muscle tissue that needs examining, use MRI, expert says ... to assess the condition of heart arteries without putting a ... tomography -- more commonly called a CT scan -- is ... of studies has found. , "For ruling out coronary artery ...
... 2010 News media and others interested in the ... a series of American Chemical Society (ACS) Webinars, Your ... pertinent career topics impacting science and engineering professionals. ... Time, the free webinar will feature Carolyn Fisher, Regulatory ...
Cached Medicine News:Health News:Later Puberty Seen for Obese Boys 2Health News:HR Allen Provides Businesses with Three New Services. 2Health News:HR Allen Provides Businesses with Three New Services. 3Health News:Luis Tiant and Sunridge International Partner to Provide Medical Relief in Cuba: Former Star Pitcher for the Red Sox and Yankees Leads the Fight Against Glaucoma 2Health News:Luis Tiant and Sunridge International Partner to Provide Medical Relief in Cuba: Former Star Pitcher for the Red Sox and Yankees Leads the Fight Against Glaucoma 3Health News:From 301 lbs Diabetic to Fast Food Six Pack Abs 2Health News:CT Scans Deemed Best for Checking Heart Arteries 2Health News:CT Scans Deemed Best for Checking Heart Arteries 3Health News:ACS webinar features tips for finding and building a career in the food and flavor industries 2
... Control is a liquid control ... busy immunoassay laboratory. With a ... serum based control can replace ... products for immunoassay and therapeutic ...
Liquichek Immunology Control is a trilevel, liquid, comprehensive serum protein control with assayed values for a wide number of methods....
... Sample Detection Platform provides fully automated detection ... new platform for molecular pathology labs separates ... software features that deliver a high degree ... has the capacity to run two 96-well ...
Invacare 5 Oxygen Concentrator with Sens O2, 230 VAC - Intl....
Medicine Products: